1. Home
  2. WERN vs AUPH Comparison

WERN vs AUPH Comparison

Compare WERN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Werner Enterprises Inc.

WERN

Werner Enterprises Inc.

SELL

Current Price

$27.60

Market Cap

2.0B

Sector

Industrials

ML Signal

SELL

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

SELL

Current Price

$15.30

Market Cap

2.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WERN
AUPH
Founded
1956
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
WERN
AUPH
Price
$27.60
$15.30
Analyst Decision
Hold
Buy
Analyst Count
16
6
Target Price
★ $36.67
$18.50
AVG Volume (30 Days)
★ 984.6K
837.4K
Earning Date
10-27-2026
10-30-2026
Dividend Yield
★ 1.98%
N/A
EPS Growth
N/A
★ N/A
EPS
0.14
★ 0.76
Revenue
★ $2,974,396,000.00
$283,055,000.00
Revenue This Year
$22.96
$16.65
Revenue Next Year
$8.31
$17.73
P/E Ratio
$201.75
★ $20.37
Revenue Growth
N/A
★ N/A
52 Week Low
$23.06
$13.52
52 Week High
$47.49
$19.25

Technical Indicators

Market Signals
Indicator
WERN
AUPH
Relative Strength Index (RSI) 38.18 35.94
Support Level $26.85 $14.76
Resistance Level $29.68 $16.48
Average True Range (ATR) 0.99 0.55
MACD 0.22 -0.16
Stochastic Oscillator 25.00 5.44

Price Performance

Historical Comparison
WERN
AUPH

About WERN Werner Enterprises Inc.

Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: